Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Literature DB >> 30100080

Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Kelly E Henry¹, Gary A Ulaner², Jason S Lewis³.

Abstract

Increased expression of the human epidermal growth factor receptor (HER) protein family are targets in breast cancer for imaging and therapy. Imaging modalities targeting HER2 and HER3 can diagnose breast cancer with a specific, biologically relevant target. Repeat biopsies do not address heterogeneity intratumorally or between primary disease and metastasis. HER2- and HER3-targeted PET is an important tool to diagnose disease in breast cancer and evaluate response to targeted therapies. PET and single photon emission computed tomography with radiolabeled biomolecules can be used to detect and quantify specific targets, conferring a better understanding of the behavior and effectiveness of treatments.

Entities: Chemical Disease Gene Species

Keywords: Breast cancer; CT; HER2; HER3; Metastasis; PET; Radiotracers; SPECT

Mesh：

Substances：

Year: 2018 PMID： 30100080 PMCID： PMC6092024 DOI： 10.1016/j.cpet.2018.02.010

Source DB: PubMed Journal: PET Clin ISSN： 1556-8598

61 in total

Review 1. Trastuzumab--mechanism of action and use in clinical practice.

Authors: Clifford A Hudis
Journal: N Engl J Med Date: 2007-07-05 Impact factor: 91.245

Review 2. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Authors: Melissa A Deri; Brian M Zeglis; Lynn C Francesconi; Jason S Lewis
Journal: Nucl Med Biol Date: 2012-09-19 Impact factor: 2.408

3. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Authors: Gary A Ulaner; Serge K Lyashchenko; Christopher Riedl; Shutian Ruan; Pat B Zanzonico; Diana Lake; Komal Jhaveri; Brian Zeglis; Jason S Lewis; Joseph A O'Donoghue
Journal: J Nucl Med Date: 2017-11-16 Impact factor: 10.057

4. Noninvasive ⁸⁹Zr-Transferrin PET Shows Improved Tumor Targeting Compared with ¹⁸F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer.

Authors: Kelly E Henry; Thomas R Dilling; Dalya Abdel-Atti; Kimberly J Edwards; Michael J Evans; Jason S Lewis
Journal: J Nucl Med Date: 2017-08-28 Impact factor: 10.057

Review 5. Intratumor Heterogeneity in Breast Cancer.

Authors: Francisco Beca; Kornelia Polyak
Journal: Adv Exp Med Biol Date: 2016 Impact factor: 2.622

6. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.

Authors: K Scheidhauer; A Scharl; U Pietrzyk; R Wagner; U J Göhring; K Schomäcker; H Schicha
Journal: Eur J Nucl Med Date: 1996-06

Review 7. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.

Authors: P D Shreve; Y Anzai; R L Wahl
Journal: Radiographics Date: 1999 Jan-Feb Impact factor: 5.333

8. ⁸⁹Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Authors: Frederike Bensch; Laetitia E Lamberts; Michaël M Smeenk; Annelies Jorritsma-Smit; Marjolijn N Lub-de Hooge; Anton G T Terwisscha van Scheltinga; Johan R de Jong; Jourik A Gietema; Carolien P Schröder; Marlene Thomas; Wolfgang Jacob; Keelara Abiraj; Celine Adessi; Georgina Meneses-Lorente; Ian James; Martin Weisser; Adrienne H Brouwers; Elisabeth G E de Vries
Journal: Clin Cancer Res Date: 2017-07-21 Impact factor: 12.531

9. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Authors: Jens Sörensen; Irina Velikyan; Dan Sandberg; Anders Wennborg; Joachim Feldwisch; Vladimir Tolmachev; Anna Orlova; Mattias Sandström; Mark Lubberink; Helena Olofsson; Jörgen Carlsson; Henrik Lindman
Journal: Theranostics Date: 2016-01-01 Impact factor: 11.556

10. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

Authors: Kathy Miller; Javier Cortes; Sara A Hurvitz; Ian E Krop; Debu Tripathy; Sunil Verma; Kaveh Riahi; Joseph G Reynolds; Thomas J Wickham; Istvan Molnar; Denise A Yardley
Journal: BMC Cancer Date: 2016-06-03 Impact factor: 4.430

8 in total

1. Polyazamacrocycle Ligands Facilitate ⁸⁹Zr Radiochemistry and Yield ⁸⁹Zr Complexes with Remarkable Stability.

Authors: Darpan N Pandya; Kelly E Henry; Cynthia S Day; Stephen A Graves; Veronica L Nagle; Thomas R Dilling; Akesh Sinha; Brandie M Ehrmann; Nikunj B Bhatt; Yusuf Menda; Jason S Lewis; Thaddeus J Wadas
Journal: Inorg Chem Date: 2020-11-10 Impact factor: 5.165

Review 2. PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies.

Authors: Matthew F Covington; Bhasker R Koppula; Gabriel C Fine; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal: Cancers (Basel) Date: 2022-05-29 Impact factor: 6.575

3. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted ⁸⁹Zr-Pertuzumab PET/CT.

Authors: Gary A Ulaner; Jorge A Carrasquillo; Christopher C Riedl; Randy Yeh; Vaios Hatzoglou; Dara S Ross; Komal Jhaveri; Sarat Chandarlapaty; David M Hyman; Brian M Zeglis; Serge K Lyashchenko; Jason S Lewis
Journal: Radiology Date: 2020-06-09 Impact factor: 11.105

Review 4. Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond.

Authors: Javad Garousi; Anna Orlova; Fredrik Y Frejd; Vladimir Tolmachev
Journal: EJNMMI Radiopharm Chem Date: 2020-06-23

5. Towards integration of ⁶⁴Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer.

Authors: Angela M Jarrett; David A Hormuth; Vikram Adhikarla; Prativa Sahoo; Daniel Abler; Lusine Tumyan; Daniel Schmolze; Joanne Mortimer; Russell C Rockne; Thomas E Yankeelov
Journal: Sci Rep Date: 2020-11-25 Impact factor: 4.379

6. ^99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer.

Authors: Paolo Rainone; Antonella De Palma; Francesco Sudati; Valentina Roffia; Valentina Rigamonti; Lucia Salvioni; Miriam Colombo; Marilena Ripamonti; Antonello Enrico Spinelli; Davide Mazza; Pierluigi Mauri; Rosa Maria Moresco; Davide Prosperi; Sara Belloli
Journal: Int J Nanomedicine Date: 2021-03-08

Review 7. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.

Authors: Sara S Rinne; Anna Orlova; Vladimir Tolmachev
Journal: Int J Mol Sci Date: 2021-04-01 Impact factor: 5.923

Review 8. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[¹⁸F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review.

Authors: John A Katzenellenbogen
Journal: Nucl Med Biol Date: 2020-02-22 Impact factor: 2.408